Loading stock data…
$87.00+0.39 (+0.45%)
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally.
Rhythm Pharmaceuticals, Inc. in the Healthcare sector is trading at $87.00 with a market capitalization of $8.0B. Wall Street consensus targets $140.35 (17 analysts), implying a +61.3% move over the next 12 months. The stock is currently 29% below its 52-week high of $122.20, remaining 11.2% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 18 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $71.25M↑ | $60.11M↑ | $57.25M↑ | $51.30M↑ | $48.50M |
| Gross Profit | $62.32M↑ | $52.95M↑ | $52.45M↑ | $45.80M↑ | $42.96M |
| Operating Income | -$48.55M↑ | -$52.36M↓ | -$47.06M↑ | -$52.65M↓ | -$45.30M |
| Net Income | -$49.30M↑ | -$55.64M↓ | -$47.51M↑ | -$52.90M↓ | -$46.63M |
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 ...